IBM's Balancing Act: Quantum Breakthroughs, AI Momentum, and a Cloud of Skepticism

IBM faces scrutiny over quantum claims, trimmed growth forecast, and securities probe; stock trades 31% below 52-week high.

The timing could hardly be more awkward. Just as IBM trumpets back-to-back quantum computing milestones, the company finds itself defending its credibility on multiple fronts — from questions about the substance behind its quantum PR to an ongoing securities probe and a trimmed growth forecast.

At the center of the tension is a stock trading at roughly €199–203, some 31–32 percent below its 52-week high of €292.85, with the 200-day moving average hovering around €226–227 — a technical picture that suggests the selling pressure hasn't fully abated.

The Quantum Narrative Under Scrutiny

IBM's quantum division delivered two consecutive demonstrations of so-called "quantum advantage." Working with Algorithmiq, the company ran a simulation of heterogeneous quantum matter on its IBM Quantum Heron system, deploying a new benchmark dubbed "monoprop." A day earlier, IBM and Qedma had outperformed a classical simulation running on the Fugaku supercomputer using a 74-qubit Floquet-Ising model paired with the QESEM error-correction method — a result IBM bills as the first quantum advantage achieved with commercial hardware and software.

Algorithmiq CEO Sabrina Maniscalco called the moment an "inflection point" for quantum computing. Yet that enthusiasm is colliding with a growing chorus of doubt. The tech portal Techrights has accused IBM of using "bought press" to mislead shareholders about quantum technology's true maturity, citing physicist Sabine Hossenfelder's critical assessment of the company's quantum communications.

The credibility question matters because IBM's investment thesis increasingly rests on its "quantum-centric supercomputing" narrative — a concept the company pitched at a recent AI summit in Seoul, where Yonsei University is slated to receive a quantum system. If the scientific substance behind the messaging doesn't hold up to independent scrutiny, institutional investors who have already absorbed significant share-price declines could lose further confidence.

A Growth Forecast That Raised Eyebrows

The skepticism isn't confined to the quantum lab. In mid-August, IBM trimmed its 2026 revenue growth outlook to 4–5 percent on a currency-adjusted basis, having previously guided for growth "above 5 percent." The company left its free cash flow target of $15.7 billion untouched — a commitment that now anchors expectations ahead of the September 10 dividend payment of $1.69 per share.

That guidance cut is the real fault line for investors. The question is whether artificial intelligence can fill the gap left by slowing core revenue. Susquehanna analyst James Friedman recently lifted his price target on IBM to $235 from $225 while keeping a "Neutral" rating, citing the mainframe upgrade cycle and the fact that AI now accounts for half of consulting signings. Whether that AI mix holds will determine if the lowered guidance is a one-off disappointment or the start of a structural growth problem.

Strategic Moves With Real Money Behind Them

Several developments suggest IBM is converting ambition into paid contracts. The $240 million deal with Together AI to build a large-scale AI inference cluster on IBM Cloud using Nvidia hardware — slated to go live in early 2027 — represents concrete infrastructure revenue rather than vaporware announcements. The completed acquisition of HRL Laboratories adds silicon-spin qubits to IBM's quantum roadmap, complementing its existing superconducting technology. And at the THINK Boston conference, IBM unveiled a collaboration with Saudi Aramco focused on AI and automation for industrial and energy systems.

The company also introduced its first dual-architecture mainframe processor at the Hot Chips event, designed to run both IBM-native and Arm-native workloads on future IBM Z and LinuxONE systems. That hardware refresh cycle is a key near-term revenue driver, alongside the consulting arm's continued momentum — evidenced by the completion of a payroll modernization project for SingHealth on SAP S/4HANA.

Research partnerships with Oak Ridge National Laboratory and the Cleveland Clinic, focused on modeling FLiBe for fusion energy applications, further suggest IBM's quantum approach is penetrating serious scientific use cases.

Warning Signs Piling Up

The bear case is equally substantive. A data breach at the Singapore Land Authority exposed personal information of 70,000 people — including names and ID numbers from a 1998 dataset — in an IBM-managed cloud environment. Such operational failures can trigger regulatory fallout and reputational damage, particularly for a vendor entrusted with sensitive government and healthcare workloads.

Institutional investors have been voting with their feet. Brendel Financial Advisors and Mitchell Capital Management slashed their IBM positions in the second quarter by high-double-digit to low-triple-digit percentages, while Pictet Asset Management also trimmed its stake. Adding to the unease, Senior Vice President Robert David Thomas sold 25,000 shares at a weighted average price of $230.32 in late August, according to an SEC filing.

The law firm BFA Law has an open investigation into potential securities fraud, centered on allegations that IBM misrepresented the pace of new business wins and its outlook for the IBM Z product line. An investigation isn't a verdict, but it keeps a risk alive that could weigh on the stock. Meanwhile, Simply Wall St lowered the consensus price target from 20 analysts to $284 from $307 — a sign skepticism has broadened even as individual firms like Susquehanna remain cautiously optimistic.

What to Watch

The immediate test comes with the September 10 dividend payment, which will signal whether IBM can honor its cash flow commitment despite the reduced growth guidance. Further out, the IEEE Quantum Week in Toronto from September 13–18 offers a competitive checkpoint, with rivals like QTREX Quantum showcasing new hardware architectures — a chance to see whether IBM's quantum lead holds up in direct comparison.

For now, the stock sits in a technical no-man's land: below all major moving averages with an RSI of 45.8, yet not far from levels where buyers have previously stepped in. The path forward hinges on whether IBM can keep the AI share of consulting signings elevated, maintain the mainframe upgrade cycle, and — perhaps most critically — convince investors that its quantum breakthroughs are scientifically verifiable rather than marketing milestones. A slide toward the 52-week low of €175.14 remains possible if the legal scrutiny intensifies or institutional selling resumes. But if the company can stabilize its growth narrative, the current valuation discount to its 200-day average could begin to close.